Treating an autoimmune disease in mice with an mRNA vaccine

January 07, 2021

Christina Krienke and colleagues have designed an mRNA vaccine that delayed the onset of and reduced the severity of multiple sclerosis-like disease in mice. The vaccine restores the body's tolerance to its own proteins, suppressing the characteristic immune overreactivity of the disease. The vaccine developed by Krienke et al. works in a targeted fashion to promote tolerance to specific disease-related proteins, an improvement over other approaches to treating the disease that induce systemic immune suppression that can leave an individual vulnerable to other infections. The vaccine consists of a lipid nanoparticle packed with modified and purified mRNA that encodes disease-related self-antigens that are normally the triggers for an autoimmune response. In their experiments in mice with autoimmune encephalomyelitis, a mouse model for human multiple sclerosis, the researchers found that the vaccine caused the antigens to be presented on lymphoid dendritic cells without provoking an inflammatory immune response. This new antigen tolerance led to the expansion of regulatory T cells that suppressed the autoimmune response against these types of antigens, and promoted the suppression of other T cells that attack proteins in myelin, the insulating sheath around nerve fibers that is destroyed in multiple sclerosis. The ability to quickly produce mRNA vaccines containing the code for an individual's own antigens may point the way to creating personalized autoimmune disease treatments, the researchers suggest.

American Association for the Advancement of Science

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to